ABSTRACT
BACKGROUND COVID-19 is associated with immune dysregulation and hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody.
METHODS Patients hospitalized with severe COVID-19 pneumonia receiving standard care were randomized (2:1) to double-blinded intravenous tocilizumab 8 mg/kg or placebo. The primary outcome measure was clinical status on a 7-category ordinal scale at day 28 (1, discharged/ready for discharge; 7, death).
RESULTS Overall, 452 patients were randomized; the modified-intention-to-treat population included 294 tocilizumab-treated and 144 placebo-treated patients. Clinical status at day 28 was not statistically significantly improved for tocilizumab versus placebo (P=0.36). Median (95% CI) ordinal scale values at day 28: 1.0 (1.0 to 1.0) for tocilizumab and 2.0 (1.0 to 4.0) for placebo (odds ratio, 1.19 [0.81 to 1.76]). There was no difference in mortality at day 28 between tocilizumab (19.7%) and placebo (19.4%) (difference, 0.3% [95% CI, –7.6 to 8.2]; nominal P=0.94). Median time to hospital discharge was 8 days shorter with tocilizumab than placebo (20.0 and 28.0, respectively; nominal P=0.037; hazard ratio 1.35 [95% CI 1.02 to 1.79]). Median duration of ICU stay was 5.8 days shorter with tocilizumab than placebo (9.8 and 15.5, respectively; nominal P=0.045). In the safety population, serious adverse events occurred in 34.9% of 295 patients in the tocilizumab arm and 38.5% of 143 in the placebo arm.
CONCLUSIONS In this randomized placebo-controlled trial in hospitalized COVID-19 pneumonia patients, tocilizumab did not improve clinical status or mortality. Potential benefits in time to hospital discharge and duration of ICU stay are being investigated in ongoing clinical trials.
Trial registration ClinicalTrials.gov NCT04320615
Competing Interest Statement
I.O.R. received a grant from Roche/Genentech during the conduct of the study; a grant and personal fees from Genentech outside the submitted work; and personal fees from Boehringer and Bristol-Myers Squibb outside the submitted work. N.B. institution received grant support from Roche/Genentech during the conduct of the study. M.W., M.S.A., N.C., I.S.D., S.S., T.Y., A.C.G., and D.J.D.L.Z. have nothing to disclose. R.G. has received consulting fees from F. Hoffmann-La Roche outside the submitted work. B.D.H. has received speaker bureau fees from Kite Pharmaceuticals outside the submitted work. S.B. has received personal fees from Gilead Sciences, Roche, and ViiV Healthcare outside the submitted work. D.S. institution received grant support from Roche/Genentech during the conduct of the study. L.D.S. received nonfinancial support from F. Hoffmann-La Roche Ltd during the conduct of the study. A.U. institution received grant support from Roche/Genentech during the conduct of the study, and he has received personal fees from Gilead Sciences outside the submitted work. M.B. and L.T. received a grant from Biomedical Advanced Research and Development Authority for the COVACTA study; are employees of Roche/Genentech; and have filed a patent for a method of treating pneumonia, including COVID-19 pneumonia, with an IL-6 antagonist. S.D. received a grant from Biomedical Advanced Research and Development Authority for the COVACTA study and is an employee and a shareholder of Roche Products Ltd. E.G. and B.M. are employees of Roche Products Ltd. H.S. is an employee and a shareholder of Roche Products Ltd. A.M. institution received grant support from Roche/Genentech during the conduct of the study; he has received funding from the National Institutes of Health outside the submitted work and medical education from Merck and Livanova outside the submitted work.
Clinical Trial
NCT04320615
Funding Statement
The study was funded by F. Hoffmann-La Roche Ltd and funded in part with federal funds received from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201800036C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained for all enrolled patients. The study was conducted in accordance with the International Council for Harmonization E6 guideline for good clinical practice and the Declaration of Helsinki or local regulations, whichever afforded greater patient protection. The protocol was reviewed by institutional review boards or ethics committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)
